Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative Colitis

Stock Information for Palatin Technologies Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Palatin Technologies Inc.

Palatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
Palatin Technologies Announces Closing of Upsized $18.2 Million Public Offering with the Full Exercise of the Underwriters' Over-Allotment Option
Palatin Reports Fiscal Year 2025 Third Quarter Results and Business Update
Palatin Presents Promising Preclinical Data on Melanocortin Agonists for Retinopathy at ARVO 2025
Palatin Technologies Announces Closing of Reduced Public Offering
Palatin Presents Breakthrough Symptom Resolution Data from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease at ARVO 2025
Palatin Technologies Announces Transition to OTC Pink Following NYSE American Delisting Notice
Palatin Expects $11.5 Million Financing to Cure NYSE American Delisting Notice

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.